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ABSTRACT
Background Early identification of patients with H1N1
influenza-related pneumonia is desirable for the early
instigation of antiviral agents. A study was undertaken to
investigate whether adults admitted to hospital with
H1N1 influenza-related pneumonia could be
distinguished clinically from patients with non-H1N1
community-acquired pneumonia (CAP).
Methods Between May 2009 and January 2010, clinical
and epidemiological data of patients with confirmed H1N1
influenza infection admitted to 75 hospitals in the UK
were collected by the Influenza Clinical Information
Network (FLU-CIN). Adults with H1N1 influenza-related
pneumonia were identified and compared with
a prospective study cohort of adults with CAP hospitalised
between September 2008 and June 2010, excluding
those admitted during the period of the pandemic.
Results Of 1046 adults with confirmed H1N1 influenza
infection in the FLU-CIN cohort, 254 (25%) had H1N1
influenza-related pneumonia on admission to hospital.
In-hospital mortality of these patients was 11.4%
compared with 14.0% in patients with inter-pandemic
CAP (n¼648). A multivariate logistic regression model
was generated by assigning one point for each of five
clinical criteria: age #65 years, mental orientation,
temperature $388C, leucocyte count #123109/l and
bilateral radiographic consolidation. A score of 4 or 5
predicted H1N1 influenza-related pneumonia with
a positive likelihood ratio of 9.0. A score of 0 or 1 had
a positive likelihood ratio of 75.7 for excluding it.
Conclusion There are substantial clinical differences
between H1N1 influenza-related pneumonia and
inter-pandemic CAP. A model based on five simple
clinical criteria enables the early identification of adults
admitted with H1N1 influenza-related pneumonia.
INTRODUCTION
In March 2009 the ﬁrst cases of a novel strain of
inﬂuenza A virus of swine origin were reported
in Mexico1 and, within 3 months, global spread
led to declaration of a pandemic by the World
Health Organization (WHO). While most cases of
pandemic inﬂuenza H1N1 infection have been mild
or subclinical,2e4 some patients experienced severe
illness from H1N1 inﬂuenza infection and others
severe inﬂuenza-related complications.5 6
Pneumonia is one of the commonest and most
important complications of inﬂuenza infection.
Inﬂuenza virus causes primary viral pneumonia,
and secondary bacterial infections are also recog-
nised.7 8 In contemporary cohorts of patients
admitted with inter-pandemic community acquired
pneumonia (CAP), inﬂuenza is frequently found as
a co-pathogen alongside other respiratory patho-
gens such as Streptococcus pneumoniae.9e12 Studies of
the 1918e19 inﬂuenza pandemic have suggested
that the majority of inﬂuenza-related deaths during
that period were caused by secondary bacterial
pneumonia.13 More recently, in hospitalised
patients with conﬁrmed H1N1 inﬂuenza infection,
radiological evidence of pneumonia was observed in
18e66% of patients.14e17 In addition, although not
necessarily the cause of death, pneumonia was
found in the majority of fatal cases at post-mortem
examination.18 19 Overall, fewer than 30% of H1N1
inﬂuenza-related pneumonia cases have evidence of
bacterial co-infection,20e22 suggesting that primary
viral pneumonia is often important.
Early identiﬁcation of patients with H1N1
inﬂuenza-related pneumonia may enable the early
administration of antiviral agents with possible
improved outcomes.23 However, there are few data
relating to the clinical differentiation of H1N1
inﬂuenza-related pneumonia from inter-pandemic
CAP. The aims of the current study were (1) to
compare and contrast the clinical features of adult
patients admitted with CAP versus H1N1 inﬂu-
enza-related pneumonia and (2) to develop a model
that identiﬁes H1N1 inﬂuenza-related pneumonia
using simple clinical criteria.
METHODS
Study patients
H1N1 influenza-related pneumonia cohort
(H1N1 cohort)
Between May 2009 and January 2010, the Inﬂuenza
Clinical Information Network (FLU-CIN) collected
clinical and epidemiological data on patients
admitted to UK hospitals with conﬁrmed
H1N1 inﬂuenza infection. Seventy-ﬁve hospitals
in 31 cities or towns were included. The details
of data collection and the overall ﬁndings from
the ﬁrst wave of the 2009 pandemic have been
described elsewhere.24 H1N1 inﬂuenza infection
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was diagnosed by a positive polymerase chain reaction (PCR)
result from respiratory samples obtained via a nasopharyngeal
swab or bronchoalveolar lavage performed during the admission
episode. Data collected included demography, clinical observa-
tions, clinical course, laboratory and radiological test results and
outcome. The current study cohort comprised adults (aged
$16 years) whose admission chest x-rays met one of the
following criteria:
1. Chest x-ray report clearly suggestive of pneumonia.25
2. Chest x-ray report showed acute inﬁltrates but no consolidation.
3. No chest x-ray report available but x-ray documented in the
clinical notes as being in keeping with pneumonia (n¼24).
Patients who had acquired H1N1 inﬂuenza infection while in
hospital or had been transferred to a study site from another
hospital (eg, for extracorporeal membrane oxygenation therapy)
were excluded.
Non-H1N1 influenza CAP cohort (CAP cohort)
Between September 2008 and June 2010, consecutive adult
patients (aged $16 years) admitted to a large UK teaching
hospital trust (Nottingham University Hospitals NHS trust)
with CAP were prospectively recruited as part of a population-
based observational cohort study. Patients were included if they
had at least one acute symptom in keeping with a lower respi-
ratory tract infection (breathlessness, cough, sputum production
or fever), had new inﬁltrates on a chest x-ray and were treated by
the admitting team for CAP. Patients were excluded if they had
been admitted to hospital in the preceding 10 days, had tuber-
culosis, or had post-obstructive pneumonia due to lung cancer.
Participants were identiﬁed by study investigators on a daily basis
from the acute admitting medical wards and enrolled following
informed consent. All patients were managed in a similar manner
according to trust CAP guidelines at the discretion of the
attending clinician. For the purposes of this analysis and to ensure
inclusion of only cases without H1N1 inﬂuenza infection,
participants were excluded if admitted during the period of H1N1
inﬂuenza circulation in Nottingham (between 30 April 2009 and
10 February 2010dthis interval comprising all cases of H1N1
inﬂuenza infection in the Nottingham area based on local Health
Protection Agency data (unpublished)).
Statistical methods
Data were analysed using SPSS Version 16.0. Continuously
distributed variables were compared between H1N1 and CAP
cohorts using the Student’s t test if data were normally distrib-
uted and the ManneWhitney U test if non-normally distributed.
Categorical data were compared using Pearson c2. In order to
derive a clinical diagnostic model for H1N1 inﬂuenza-related
pneumonia, continuously distributed variables were re-cate-
gorised into binary variables based on thresholds derived from
established acute severity scores (CURB-65 score,26 Pneumonia
Severity Index,27 Surviving Sepsis Campaign28) and univariate
analysis using c2 allowed calculation of odds ratios with 95%
conﬁdence intervals. Variables for inclusion in the ﬁnal model
were selected using automatic stepwise regression with both
forwards (selection) and backwards (deletion) variants. The
efﬁcacy of the model for predicting H1N1 inﬂuenza-related
pneumonia was then assessed by calculating the area under the
curve (AUC) of the receiver-operating characteristic (ROC) curve.
RESULTS
Patient characteristics
Of 1046 adults with conﬁrmed H1N1 inﬂuenza infection in the
FLU-CIN cohort, 266 (25.4%) had evidence of either radiographic
consolidation or other inﬁltrates consistent with acute infection.
Twelve patients were transferred in from hospitals outside the
study area or developed inﬂuenza infection while already an
inpatient, leaving a study cohort of 254 patients (H1N1 cohort).
The comparator group comprised 648 patients with inter-
pandemic CAP (CAP cohort). The patient characteristics are
summarised in table 1 and the relative age distribution of both
cohorts is shown in ﬁgure 1. Despite having similar in-hospital
mortality (H1N1 cohort 11.4%; CAP cohort 14.0%), the two
groups differed substantially. The median age of patients in the
H1N1 cohort was 42 years compared with 75 years in the CAP
cohort (p<0.001). The most common comorbid illnesses in the
H1N1 cohort were asthma (25.2%) and diabetes mellitus (9.8%)
compared with chronic obstructive pulmonary disease (COPD)
(26.1%) and diabetes mellitus (15.4%) in the CAP cohort. In the
H1N1 cohort, 9.4% of patients had $3 comorbid illnesses
compared with 11.9% of controls. In addition, patients in the
H1N1 cohort were more likely to be febrile, tachycardic, have
bilateral radiographic abnormalities and have lower leucocyte
counts and levels of C-reactive protein. Confusion, comorbidity
and blood urea levels were higher among patients in the CAP
cohort. Within the H1N1 cohort, 11 (4.3%) were pregnant and 21
(8.3%) were obese. The value of the CURB-65 score in predicting
inpatient mortality was assessed by calculating the AUC for
ROC curves for each group; the AUC for the H1N1 cohort was
0.650 compared with 0.741 for the CAP cohort.
Derivation of a clinical model for the diagnosis of H1N1
influenza-related pneumonia
Nine categorical variables were found to be associated with
H1N1 inﬂuenza-related pneumonia on univariate analysis
(table 2). Two of these variables (C-reactive protein and
albumin) were excluded from the derivation of the diagnostic
prediction model because they are not routinely performed on
admission in all hospitals for acutely ill patients. In a logistic
regression model, ﬁve of the seven variables were found to be
statistically signiﬁcant at the 5% level (table 3). These variables
remained statistically signiﬁcant using both forwards and
backwards stepwise regression models. The resulting 5-point
score generated a ROC curve AUC of 0.873 (based on 858 data
points). The derived score stratiﬁes patients into three risk
groups for H1N1 inﬂuenza-related pneumonia as shown in
table 4. In order to assess the impact of age on the discriminant
model, a further analysis was undertaken with age excluded
from the logistic regression analysis, leaving the four variables of
bilateral radiographic consolidation, mental orientation, leuco-
cyte count #123109/l and temperature $388C. The resulting
ORs were 3.0 (95% CI 2.0 to 4.4), 6.3 (95% CI 3.5 to 11.5), 9.4
(95% CI 6.3 to 14.3) and 2.6 (95% CI 1.8 to 3.8), respectively.
The ROC curve AUC for this model was 0.806. Use of age
#65 years as a single binary predictor gave an AUC of 0.794.
C-reactive protein and albumin were excluded from the initial
logistic regression analysis in order to maximise clinical utility of
the algorithm. When both variables were included as part of
a multivariate analysis for exploratory purposes (H1N1 cohort,
n¼123; CAP cohort, n¼456), only albumin #30 g/dl was
statistically signiﬁcant at the 5% level (OR 1.9; 95% CI 1.1 to
3.5). The ﬁve previously described variables of age #65 years,
bilateral radiographic consolidation, mental orientation, leuco-
cyte count #123109/l and temperature $388C remained
statistically signiﬁcant within the model.
As the age proﬁles of the two cohorts were signiﬁcantly
different and age may be a surrogate for other confounding
factors, a secondary analysis was undertaken including only
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those patients aged <65 years (H1N1 cohort, n¼228; CAP
cohort, n¼200). Within this subgroup, median age remained
signiﬁcantly different (39 years vs 50 years; p<0.001). In
a logistic regression analysis, leucocyte count #123109/l (OR
10.1, 95% CI 6.1 to 16.7), age #50 years (OR 2.7, 95% CI 1.6 to
4.4), bilateral radiographic change (OR 2.5, 95% CI 1.5 to 4.4)
and temperature $388C (OR 2.1, 95% CI 1.3 to 3.4) were the
only signiﬁcant contributors to the ﬁnal model. Using this
model to predict H1N1 inﬂuenza-related pneumonia, the AUC
for the ROC curve was 0.789.
A model to distinguish H1N1 inﬂuenza-related pneumonia
based solely on physiological and radiological variables available
rapidly in the emergency department (ie, excluding laboratory
results) is shown in the online supplement.
DISCUSSION
To our knowledge, this is the ﬁrst study to highlight the
clinical differences between inter-pandemic CAP and H1N1
Figure 1 Age distribution of patients with H1N1 influenza-related
pneumonia (group A) compared with community-acquired pneumonia
(group B).
Table 1 Clinical characteristics of patients with H1N1 influenza-related pneumonia compared with
community-acquired pneumonia (CAP)
Characteristic H1N1 cohort (n[254) CAP cohort (n[648) p Value
Demographics
Age (years) 42 (29e54) 75 (61e84) <0.001
Male 109 (42.9%) 367 (56.6%) <0.001
Admission observations
Temperature (8C), mean (95% CI) 38.1 (37.9 to 38.2) (n¼245) 37.5 (37.4 to 37.6) (n¼644) <0.001
Pulse (/min) 110 (97e120) (n¼244) 100 (86e115) (n¼646) <0.001
SBP (mm Hg), mean (95% CI) 125 (123 to 128) (n¼243) 126 (124 to 129) (n¼646) 0.61
Respiratory rate (/min) 24 (19e28) (n¼240) 22 (18e28) (n¼646) 0.14
Confusion 18 (7.1%) 182 (28.1%) <0.001
Outcome
Critical care admission 88 (34.6%) 83 (12.8%) <0.001
LOS for survivors (days) 6 (3e11) (n¼206) 8 (4e14) (n¼553) 0.003
Inpatient death 29 (11.4%) 91 (14.0%) 0.296
Investigations
Bilateral consolidation 89 (39.0% of 228) 129 (19.9%) <0.001
White cell count (3109/l) 7.6 (5.4e11.3) (n¼239) 14.5 (10.5e19.9) (n¼646) <0.001
Urea (mmol/l) 4.7 (3.3e6.9) (n¼232) 7.9 (5.5e12.6) (n¼647) <0.001
C-reactive protein (mg/l) 85 (34e199) (n¼184) 148 (61e248) (n¼602) <0.001
Albumin (g/dl) 34 (30e40) (n¼177) 31 (27e35) (n¼488) <0.001
Symptoms
Productive cough 147 (57.9%) 287 (58.7% of 489*) 0.83
Dyspnoea 151 (59.4%) 428 (87.5% of 489*) <0.001
Comorbidity
Asthma 64 (25.2%) 57 (8.8%) <0.001
COPD 24 (9.4%) 169 (26.1%) <0.001
CCF 1 (0.4%) 46 (7.1%) <0.001
Diabetes mellitus 25 (9.8%) 100 (15.4%) 0.029
Charlson index, mean (95% CI) 1.11 (0.94 to 1.27) 1.33 (1.23 to 1.44) 0.023
Values are median (IQR) or n (%) of patients unless otherwise stated. Normally distributed data are reported as means with 95% CI and
non-normally distributed data as medians with interquartile range.
*Data not given for patients with confusion.
CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; CCF, congestive cardiac failure; LOS, length of
hospital stay; SBP, systolic blood pressure.
Table 2 Univariate association between selected clinical
characteristics and presence of H1N1 infection
Characteristic
H1N1
cohort
CAP
cohort OR 95% CI p Value
Age #65 years 228/254 200/648 19.6 12.7 to 30.3 <0.001
White cell count #123109/l 189/239 222/646 7.2 5.1 to 10.3 <0.001
Oriented in time/place/person 236/254 466/648 5.1 3.1 to 8.5 <0.001
Urea <7 mmol/l 175/232 270/647 4.3 3.1 to 6.0 <0.001
Temperature $388C 142/245 232/644 2.5 1.8 to 3.3 <0.001
Bilateral x-ray change 89/228 129/648 2.6 1.9 to 3.6 <0.001
CRP #50 mg/l 67/184 126/602 2.2 1.5 to 3.1 <0.001
Albumin #30 g/dl 44/177 189/488 1.9 1.3 to 2.8 0.001
Female sex 145/254 281/648 1.7 1.3 to 2.3 0.001
Pulse $125/min 45/244 107/646 1.1 0.8 to 1.7 0.51
CAP, community-acquired pneumonia; CRP, C-reactive protein.
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inﬂuenza-related pneumonia. Patients with H1N1 inﬂuenza-
related pneumonia were signiﬁcantly younger than patients
with CAP, reﬂecting the epidemiology of H1N1 inﬂuenza
infection globally.2 14 24 29 30 This may relate to previous
exposure of older persons to pre-2009 H1N1 inﬂuenza viruses
conferring some immunity.31e33 In future years, as the virus
evolves, the epidemiology of H1N1 infection may alter to affect
older persons to a greater extent. Such a shift would also impact
on the age distribution of patients developing H1N1 inﬂuenza-
related pneumonia with potentially important consequences on
resultant morbidity and mortality. Studies of CAP conducted in
inter-pandemic years demonstrate an association between
extremes of age or frailty and inﬂuenza or viral infection.10 11
Lower levels of C-reactive protein and leucocytes were
observed in patients with H1N1 inﬂuenza-related pneumonia.
This ﬁnding is consistent with reports from studies of inter-
pandemic inﬂuenza-related pneumonia of relatively low
leucocyte, neutrophil and C-reactive protein levels.10e12 These
markers of inﬂammation are driven mainly by bacterial infec-
tions, and the predominance of primary viral pneumonia as
opposed to secondary bacterial pneumonia in H1N1 inﬂuenza-
related pneumonia may therefore partially account for this
observation.16 34 Despite the lower levels of C-reactive protein
and leucocytes, patients with H1N1 inﬂuenza-related pneu-
monia had higher levels of fever than patients with CAP. This
may be related to high levels of production of proinﬂammatory
cytokines, particularly interleukin 6,35 with reduced innate and
adaptive responses to S pneumoniae seen with pandemic H1N1
inﬂuenza.36 It may also partially reﬂect the relative inability of
older subjects to mount a febrile response to serious infection.37
A diagnostic prediction model was derived from ﬁve simple
clinical criteriadage #65 years, presence of bilateral radio-
graphic consolidation, absence of confusion as measured by
orientation in time, place or person, leucocyte count #123109/l
and temperature $388C. Assigning one point for each clinical
criterion present, a score of 4 or 5 gave a positive likelihood ratio
of 9.0 for predicting H1N1 inﬂuenza-related pneumonia, while
a score of 0 or 1 gave a positive likelihood ratio of 75.7 for e-
xcluding H1N1 inﬂuenza-related pneumonia. Although age is by
far the single strongest predictor (OR 19.6), its predictive value is
inferior to the proposed model comprising ﬁve variables. When
age was removed from the proposed model, the remaining
four variablesdbilateral radiographic consolidation, mental
orientation, leucocyte count #123109/l and temperature
$388Cdretained their signiﬁcance as independent predictors of
H1N1 inﬂuenza-related pneumonia, attesting to their impor-
tance within the model. This model is applicable at the time of
admission when a diagnosis of CAP is determined and would be
useful in aiding the early diagnosis of patients with H1N1
inﬂuenza-related pneumonia as well as management decisions
relating to infection control and the instigation of early empir-
ical antiviral therapy. Although the efﬁcacy of antiviral agents in
the treatment of patients hospitalised with inﬂuenza-related
pneumonia is not scientiﬁcally proven,38 evidence from obser-
vational studies in hospital settings suggests that early antiviral
use does improve clinical outcomes.14 23 39 40
Currently, this diagnostic prediction model can only be
advocated for H1N1 inﬂuenza-related pneumonia. It should not
be applied to other viral pneumonias without further validation.
Similarly, should pandemic inﬂuenza A/H1N1 2009 evolve and
affect older persons more widely, the predictive value of the
model is likely to be altered.
Disease severity assessment is crucial in the management of
patients with pneumonia. The CURB-65 severity assessment
score has been validated for use in predicting 30-day mortality in
patients with CAP26 and was advocated as potentially useful in
patients with inﬂuenza-related pneumonia.41 42 However, this
study suggests that, in patients with H1N1 inﬂuenza-related
pneumonia, the CURB-65 score does not perform so well. This
difference may be due to a combination of features including
the lower age distribution and comorbidity proﬁle of patients
with H1N1 inﬂuenza-related pneumonia and differences in
the inﬂammatory response to H1N1 inﬂuenza infection.43
Further study of the prognostic factors relevant to H1N1
inﬂuenza-related pneumonia is warranted.
Study limitations
The main limitation to this study is that the CAP cohort was
not collected contemporaneously with the H1N1 cohort and,
while the latter patients were distributed nationally, patients in
the CAP cohort were recruited from a single study centre.
Patients in the CAP cohort were prospectively enrolled as part of
a population-based cohort study involving all patients hospi-
talised with CAP in the Nottingham area (catchment popula-
tion 750 000). Nottingham has a record of conducting large
cohort studies of CAP.44e47 The age and demographics of this
CAP study cohort mirror the demographics of patients with
CAP described in a recently completed national multicentre
audit of CAP organised by the British Thoracic Society
(unpublished data). These factors support the view that the
CAP cohort is representative of patients admitted to hospital
with CAP.
Patients recruited to the FLU-CIN cohort were identiﬁed
following testing for H1N1 inﬂuenza on the basis of clinical
suspicion rather than rigorously applied testing criteria. Never-
theless, the FLU-CIN cohort is similar to other large published
H1N1 inﬂuenza cohorts in terms of clinical features and
rates of pneumonia (22e37%) and critical care admission
(13e25%).14 48 49 17 These observations suggest that the
FLU-CIN cohort is indeed representative of patients hospitalised
with H1N1 infection in the UK and is not biased in relation to
patients with inﬂuenza-related pneumonia or patients with
severe disease.
Table 3 Multivariate analysis of variables associated with H1N1
influenza-related pneumonia
Characteristic Odds ratio 95% CI p Value
Age #65 years 12.7 7.2 to 22.2 <0.001
White cell count #123109/l 9.7 6.1 to 15.6 <0.001
Bilateral radiographic change 3.3 2.1 to 5.4 <0.001
Oriented in time/place/person 2.6 1.2 to 5.3 0.012
Temperature $388C 1.9 1.3 to 3.0 0.003
Female sex 1.4 0.9 to 2.2 0.09
Urea <7 mmol/l 1.4 0.8 to 2.3 0.214
Complete data on all seven variables were available in 205 patients in the H1N1 cohort and
642 patients in the community-acquired pneumonia cohort.
Table 4 Proportions of patients identified with H1N1 influenza-related pneumonia according to the diagnostic prediction model
Score* 0 1 2 3 4 5
Proportion with H1N1 pneumonia 0/55 (0%) 1/171 (0.6%) 24/250 (9.6%) 65/214 (30.3%) 95/133 (71.4%) 31/35 (88.6%)
*One point for the presence of each of: age #65 years, white cell count #123109/l, bilateral radiographic change, oriented in time/place/person and temperature $388C.
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All patients with H1N1 inﬂuenza-related pneumonia had
laboratory-conﬁrmed pandemic H1N1 inﬂuenza infection so
misclassiﬁcation is eliminated. In contrast, it remains possible
that the CAP cohort may have contained patients in whom the
precipitating cause of pneumonia was inﬂuenza, despite the
exclusion of patients admitted with CAP during the period
when pandemic H1N1 inﬂuenza was circulating in the study
catchment population. The inclusion of some individuals with
inﬂuenza-related pneumonia within the CAP cohort would tend
towards increasing the similarities between the two groups
thereby producing underestimates of any differences.
CONCLUSIONS
H1N1 inﬂuenza-related pneumonia differs substantially from
inter-pandemic CAP. A diagnostic prediction model based on
the ﬁve clinical features of age (#65 years), leucocyte count
(#123109/l), bilateral radiographic change, temperature ($388C)
and mental orientation (time/person/place) allows the early
discrimination of H1N1 inﬂuenza-related pneumonia from CAP
following hospital admission and confers conﬁdence to the
instigation of early empirical antiviral therapy.
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